Expression of the adaptor protein Lnk in leukemia cells

Experimental Hematology

Volumn 37, Issue 5, 2009, Pages

  Gery, Sigal ^a   Gueller, Saskia ^a   Nowak, Verena ^a   Sohn, Julia ^a   Hofmann, Wolf K ^b   Koeffler, H Phillip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ADAPTOR PROTEIN LNK; BCR ABL PROTEIN; JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION;

ALLELES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; MYELODYSPLASTIC SYNDROMES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; TOR SERINE-THREONINE KINASES;

EID: 64249098439     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.01.009     Document Type: Article

References (36)

1. Baker S.J., Rane S.G., and Reddy E.P. Hematopoietic cytokine receptor signaling. Oncogene 26 (2007) 6724-6737
2. Robb L. Cytokine receptors and hematopoietic differentiation. Oncogene 26 (2007) 6715-6723
3. Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene 26 (2007) 6738-6749
4. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5 (2005) 172-183
5. Tefferi A., and Gilliland D.G. Oncogenes in myeloproliferative disorders. Cell Cycle 6 (2007) 550-566
6. Campbell P.J., and Green A.R. The myeloproliferative disorders. N Engl J Med 355 (2006) 2452-2466
7. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
8. Metcalfe D.D. Mast cells and mastocytosis. Blood 112 (2008) 946-956
9. Rudd C.E. Lnk adaptor: novel negative regulator of B cell lymphopoiesis. Sci STKE (2001) 2001(85):PE1
10. Maures T.J., and Kurzer J.H. Carter-Su C. SH2B1 (SH2-B) and JAK2: a multifunctional adaptor protein and kinase made for each other. Trends Endocrinol Metab 18 (2007) 38-45
11. Ahmed Z., and Pillay T.S. Functional effects of APS and SH2-B on insulin receptor signaling. Biochem Soc Trans Pt 4 (2001) 529-534
12. Takaki S., Morita H., Tezuka Y., and Takatsu K. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein. Lnk. J Exp Med 195 (2002) 151-160
13. Velazquez L., Cheng A.M., Fleming H.E., et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med 195 (2002) 1599-1611
14. Buza-Vidas N., Antonchuk J., Qian H., et al. Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. Genes Dev 20 (2006) 2018-2023
15. Seita J., Ema H., Ooehara J., et al. Lnk negatively regulates self-renewal of hematopoietic stem cells by modifying thrombopoietin-mediated signal transduction. Proc Natl Acad Sci U S A 104 (2007) 2349-2354
16. Tong W., and Lodish H.F. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis. J Exp Med 200 (2004) 569-580
17. Tong W., Zhang J., and Lodish H.F. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways. Blood 105 (2005) 4604-4612
18. Bersenev A., Wu C., Balcerek J., and Tong W. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. J Clin Invest 18 (2008) 2832-2844
19. Fitau J., Boulday G., Coulon F., Quillard T., and Charreau B. The adaptor molecule Lnk negatively regulates tumor necrosis factor-alpha-dependent VCAM-1 expression in endothelial cells through inhibition of the ERK1 and -2 pathways. J Biol Chem. 281 (2006) 20148-20159
20. Gery S., Gueller S., Chumakova K., et al. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders. Blood 110 (2007) 3360-3364
21. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356 (2007) 459-468
22. Zaleskas V.M., Krause D.S., Lazarides K., et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE 1 (2006) e18
23. Tian Q., Frierson Jr. H.F., Krystal G.W., and Moskaluk C.A. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154 (1999) 1643-1647
24. D'Andrea A.D., Lodish H.F., and Wong G.G. Expression cloning of the murine erythropoietin receptor. Cell 57 (1989) 277-285
25. McLaughlin J., Cheng D., Singer O., et al. Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proc Natl Acad Sci U S A 104 (2007) 20501-20506
26. Lu X., Levine R., Tong W., et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 102 (2005) 18962-18967
27. Gueller S., Gery S., and Koeffler H.P. Adaptor protein Lnk binds to PDGFRA, PDGFRB and FIP1L1-PDGFRA, but not to the TEL-PDGFRB fusion protein. Blood (ASH Annual Meeting Abstracts) 110 (2007) 2213
28. Nobuhisa I., Tazizawa M., Takaki S., et al. Regulation of hematopoietic development in the aorta-gonad-mesonephros region mediated by Lnk adaptor protein. Mol Cell Biol 23 (2003) 8486-8494
29. Takaki S., Tezuka Y., Sauer K., et al. Impaired lymphopoiesis and altered B cell subpopulations in mice overexpressing Lnk adaptor protein. J Immunol 170 (2003) 703-710
30. Huang X., Li Y., Tanaka K., Moore K.G., and Hayashi J.I. Cloning and characterization of Lnk, a signal transduction protein that links T-cell receptor activation signal to phospholipase C gamma 1, Grb2, and phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 92 (1995) 11618-11622
31. Million R.P., and Van Etten R.A. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96 (2000) 664-670
32. Ren S.Y., Bolton E., Mohi M.G., Morrione A., Neel B.G., and Skorski T. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences. Mol Cell Biol 25 (2005) 8001-8008
33. Schittenhelm M.M., Shiraga S., Schroeder A., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66 (2006) 473-481
34. Carter T.A., Wodicka L.M., Shah N.P., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102 (2005) 11011-11016
35. Spiekermann K., Faber F., Voswinckel R., and Hiddemann W. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol 30 (2002) 767-773
36. Beghini A., Bellini M., Magnani I., et al. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Exp Hematol 33 (2005) 682-688